Navigation Links
Palatin Technologies Reports Successful Completion Of Device Bioequivalence Trial

CRANBURY, N.J., Oct. 28, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced the successful completion of a clinical trial designed to demonstrate equivalence of subcutaneously administered bremelanotide via autoinjector compared to pre-filled syringe administration. Bioequivalence was achieved in this clinical trial. Palatin used pre-filled syringes in its Phase 2 clinical trials, but will use the single-dose disposable autoinjector in its planned Phase 3 clinical trials and for commercialization.

Stephen T. Wills, Chief Operating Officer and Chief Financial Officer of Palatin Technologies, commented, "Demonstrating bioequivalence in this study allows us to move forward with confidence regarding the delivery of bremelanotide via autoinjector. The pharmacokinetic profile of bremelanotide using the autoinjector device was consistent with the pharmacokinetic data collected in our completed positive Phase 2B study which used pre-filled syringes. The single-dose disposable autoinjector provides patients with a safe, easy to use device for the delivery of bremelanotide."

The design was a single-center, randomized, double-blind (to device administration) study in 36 healthy female subjects to determine the bioequivalence of 1.75 mg of bremelanotide administered by two different devices. There were no serious adverse events reported and there were no discontinuations in the study.

About Female Sexual Dysfunction
Female Sexual Dysfunction (FSD) covers multi-factorial conditions that have anatomical, physiological, medical, psychological and social components. FSD includes four categories: Sexual Desire Disorders (hypoactive sexual desire disorder [HSDD], sexual aversion disorder), Female Sexual Arousal Disorder (FSAD), Female Orgasmic Disorder (FOD), and Sexual Pain Disorders (dyspareunia, vaginismus). To establish a diagnosis of FSD, one or more of these disorders must be associated with personal distress, as determined by the affected women. In the 2006 PRESIDE study (Prevalence of Female Sexual Problems Associated with Distress and Determinants of Treatment Seeking, reference: Obstet Gynecol 2008 Nov; 112(5):970-8), Shifren and colleagues studied over 30,000 US women, reporting an age-adjusted point prevalence of sexual difficulties causing personal distress in 12% of respondents.

There are no drugs in the United States approved for the treatment of FSD.  Bremelanotide is an on-demand treatment for FSD with the potential to transform the treatment of patients with FSD.

Bremelanotide for Female Sexual Dysfunction
Palatin is developing subcutaneously administered bremelanotide for the treatment of FSD in premenopausal women diagnosed with FSD. Bremelanotide, which is a melanocortin agonist (a compound which binds to a cell receptor and triggers a response) drug candidate, is a synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone).

About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Palatin Technologies Announces Last Patient Completed Treatment In Phase 2B Bremelanotide Female Sexual Dysfunction Trial
2. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides
3. Palatin Technologies, Inc. To Report Fiscal Year 2013 Fourth Quarter Results
4. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2013 Results
5. West Physics Consulting Teams with Mirion Technologies Dosimetry Services Division to Deliver Radiation Detection Services
6. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
7. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
8. BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
9. Global Ablation Technologies Market worth $12.4 Billion by 2016: MarketsandMarkets
10. ICU Medical, Inc. Plans to "Vigorously Seek to Collect Damages" in wake of Patent Infringement Victory Over RyMed Technologies
11. BioStorage Technologies to Lead Discussion on the Value of a Comprehensive Sample Management Strategy
Post Your Comments:
(Date:10/4/2017)... Centers for Disease Control and Prevention (CDC), influenza vaccination should take ... communities across Massachusetts , Connecticut , ... through the end of the month. *Some exclusions apply ... ... by the end of October, according to the Centers for Disease Control ...
(Date:10/2/2017)... INDIANAPOLIS , Oct. 2, 2017  Eli Lilly ... its financial results for the third quarter of 2017 ... a conference call on that day with the investment ... performance. The conference call will begin at ... public can access a live webcast of the conference ...
(Date:10/2/2017)... The Rebound mobile app is poised to become ... tide of prescription drug addiction. The app empowers users to ... stepping down their dosage in a safe, controlled manner while ... the first 100,000 people to sign up will enjoy 3 ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 2017 , ... Many families have long-term insurance that covers care for a ... waiver for care if the client has a cognitive impairment diagnosis. , “What ... is often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... viewers the lowdown on sciatica in a new episode of "Success Files," which ... current events and innovation and investigates each subject in-depth with passion and integrity. ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a ... health care, have expanded their existing home health joint venture through an agreement, ... been operating a joint venture home health company with Asante, delivering clinically integrated ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the ... – Miles by Moonlight to raise money for the American Heart Association Heart Walk. ... , Teams will work together to keep their treadmills moving for 5 hours. Treadmills ...
Breaking Medicine News(10 mins):